EP-2104R: a fibrin-specific gadolinium-Based MRI contrast agent for detection of thrombus.
Thrombus (blood clot) is implicated in a number of life threatening diseases, e.g., heart attack, stroke, pulmonary embolism. EP-2104R is an MRI contrast agent designed to detect thrombus by binding to the protein fibrin, present in all thrombi. EP-2104R comprises an 11 amino acid peptide derivatized with 2 GdDOTA-like moieties at both the C- and N-terminus of the peptide (4 Gd in total). EP-2104R was synthesized by a mixture of solid phase and solution techniques. The La(III) analogue was characterized by and 1D and 2D NMR spectroscopy and was found to have the expected structure. EP-2104R was found to be significantly more inert to Gd(III) loss than commercial contrast agents. At the most extreme conditions tested (pH 3, 60 degrees C, 96 hrs), less than 10% of Gd was removed from EP-2104R by a challenge with a DTPA based ligand, while the commercial contrast agents equilibrated within minutes to hours. EP-2104R binds equally to two sites on human fibrin (Kd = 1.7 +/- 0.5 microM) and has a similar affinity to mouse, rat, rabbit, pig, and dog fibrin. EP-2104R has excellent specificity for fibrin over fibrinogen (over 100-fold) and for fibrin over serum albumin (over 1000-fold). The relaxivity of EP-2104R bound to fibrin at 37 degrees C and 1.4 T was 71.4 mM(-1) s(-1) per molecule of EP-2104R (17.4 per Gd), about 25 times higher than that of GdDOTA measured under the same conditions. Strong fibrin binding, fibrin selectivity, and high molecular relaxivity enable EP-2104R to detect blood clots in vivo.
Overoye-Chan
Kirsten
K
EPIX Pharmaceuticals, 4 Maguire Road, Lexington, Massachusetts 02421, USA.
Koerner
Steffi
S
Looby
Richard J
RJ
Kolodziej
Andrew F
AF
Zech
Stephan G
SG
Deng
Qing
Q
Chasse
Jaclyn M
JM
McMurry
Thomas J
TJ
Caravan
Peter
P
D003287:Contrast Media / Q000737:chemistry* / Q000378:metabolism; D005337:Fibrin / Q000737:chemistry / Q000378:metabolism; D005340:Fibrinogen / Q000737:chemistry / Q000378:metabolism; D005682:Gadolinium / Q000097:blood* / Q000737:chemistry*; D006571:Heterocyclic Compounds / Q000097:blood / Q000737:chemistry; D006801:Humans; D007700:Kinetics; D018810:Magnetic Resonance Angiography / Q000379:methods*; D019906:Nuclear Magnetic Resonance, Biomolecular / Q000379:methods; D009942:Organometallic Compounds / Q000097:blood / Q000737:chemistry; D010455:Peptides / Q000097:blood* / Q000737:chemistry*; D011485:Protein Binding; D013379:Substrate Specificity; D013816:Thermodynamics; D013927:Thrombosis / Q000097:blood* / Q000175:diagnosis
D003287:Contrast Media; C503783:EP-2104R; D006571:Heterocyclic Compounds; D009942:Organometallic Compounds; D010455:Peptides; D005337:Fibrin; D005340:Fibrinogen; C050823:gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate; D005682:Gadolinium